Pancreatic Cancer Research

ResearcherSingHealthActive in the last 2 years

David Wai-Meng Tai

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-2612-0065; OpenAlex author ID A5089860988, A5104050845, A5122794720. Sources: ClinicalTrials.gov.

Their work

Papers
10 (first author 0, last author 1)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
59
Papers, trials and grants by year

2018: 1 paper, 1 trial · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: none · 2025: 2 papers · 2026: 4 papers

Papers 10

  1. A tumor microenvironment integrated (TMI) staging system for pancreatic ductal adenocarcinoma based on cancer-associated fibroblast and molecular consensus sig… Co-author DOI 10.1007/s12672-026-05091-0↗
  2. Neoadjuvant therapy versus upfront surgery for resectable pancreatic cancer: Updated systematic review, individual-patient-data meta-analysis and trial sequent… Co-author DOI 10.1016/j.surg.2025.109872↗
  3. Predicting recurrence patterns and outcomes following resection of pancreatic ductal adenocarcinoma: a contemporary real-world data cohort study. Co-author DOI 10.1097/ms9.0000000000004919↗
  4. Biomarker Analysis from Patients with Metastatic PDAC Treated with TGFβ Antibody NIS793 plus Abraxane + Gemcitabine versus Abraxane + Gemcitabine Alone in a Ph… Co-author DOI 10.1158/1078-0432.ccr-26-0805↗
  5. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with pancreatic cancer. Co-author DOI 10.1016/j.esmoop.2025.105826↗
  6. Clinical Outcomes of Neoadjuvant Therapy Versus Upfront Surgery in Resectable Pancreatic Cancer: Systematic Review and Meta-analysis of Latest Randomized Contr… Co-author DOI 10.1245/s10434-024-16674-y↗
  7. A phase 1b study of OXIRI in pancreatic adenocarcinoma patients and its immunomodulatory effects. Co-author DOI 10.1002/ijc.34021↗
  8. Resected pancreatic adenocarcinoma: An Asian institution's experience. Last author DOI 10.1002/cnr2.1393↗
  9. Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer. Co-author DOI 10.1093/annonc/mdz200↗
  10. Metabolomic prediction of treatment outcome in pancreatic ductal adenocarcinoma patients receiving gemcitabine. Co-author DOI 10.1007/s00280-017-3475-6↗

Trials 1

  1. Study of Trametinib and Ruxolitinib in Colorectal Cancer and Pancreatic Adenocarcinoma Principal investigator NCT04303403↗

Closest collaborators

The 25 strongest of 59 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ye Xin Koh · 3 shared papers, 2021–2026 · strength 0.65
  2. Kennedy Yao Yi Ng · 3 shared papers, 2021–2026 · strength 0.65
  3. Brian K. P. Goh · 3 shared papers, 2021–2026 · strength 0.65
  4. Hwee Leong Tan · 2 shared papers, 2025–2026 · strength 0.55
  5. Yun Zhao · 2 shared papers, 2025–2026 · strength 0.55
  6. J H Chan · 1 shared paper, 2026 · strength 0.36
  7. Samuel Jianjie Yeo · 1 shared paper, 2026 · strength 0.36
  8. Matthew Burge · 2 shared papers, 2019–2026 · strength 0.30
  9. Mehrdad Nikfarjam · 2 shared papers, 2019–2026 · strength 0.30
  10. Belinda Lee · 2 shared papers, 2019–2026 · strength 0.30
  11. Anna Ho Yin Chan · 1 shared paper, 2025 · strength 0.25
  12. Benjamin P. T. Loveday · 1 shared paper, 2026 · strength 0.24
  13. Amitesh Chandra Roy · 1 shared paper, 2026 · strength 0.24
  14. Eden Mane · 1 shared paper, 2026 · strength 0.24
  15. Viviana Cremasco · 1 shared paper, 2026 · strength 0.20
  16. Marc R. Pelletier · 1 shared paper, 2026 · strength 0.20
  17. Mark Wong · 1 shared paper, 2026 · strength 0.20
  18. Li‐Yuan Bai · 1 shared paper, 2026 · strength 0.20
  19. Michèle Milella · 1 shared paper, 2026 · strength 0.20
  20. Bruno Bockorny · 1 shared paper, 2026 · strength 0.20
  21. Gerald W. Prager · 1 shared paper, 2026 · strength 0.20
  22. Shivan Sivakumar · 1 shared paper, 2026 · strength 0.20
  23. Teresa Mercade Macarulla · 1 shared paper, 2026 · strength 0.20
  24. Krittiya Korphaisarn · 1 shared paper, 2025 · strength 0.17
  25. Thierry Conroy · 1 shared paper, 2025 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.